AbbVie Inc. (VIE:ABBV)
Austria · Delayed Price · Currency is EUR | Market Cap | 429.89B +23.8% |
| Revenue (ttm) | 56.36B +10.4% |
| Net Income | 5.49B +67.7% |
| EPS | 3.10 +68.5% |
| Shares Out | n/a |
| PE Ratio | 78.33 |
| Forward PE | 18.06 |
| Dividend | 5.96 (2.50%) |
| Ex-Dividend Date | Oct 15, 2026 |
| Volume | n/a |
| Open | 242.90 |
| Previous Close | 244.50 |
| Day's Range | 238.40 - 243.50 |
| 52-Week Range | 164.30 - 244.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About AbbVie
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medi... [Read more]
Financial Performance
In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.19 billion, a decrease of -1.23%.
Financial numbers in USD Financial StatementsNews
AbbVie price target raised to $305 from $289 at BofA
BofA raised the firm’s price target on AbbVie (ABBV) to $305 from $289 and keeps a Buy rating on the shares as part of the firm’s Q3 EPS preview for…
AbbVie price target raised to $300 from $285 at JPMorgan
JPMorgan analyst Chris Schott raised the firm’s price target on AbbVie (ABBV) to $300 from $285 and keeps an Overweight rating on the shares ahead of the Q3 report. The…
AbbVie price target raised to $290 from $285 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on AbbVie (ABBV) to $290 from $285 and keeps an Overweight rating on the shares. Skyrizi and Rinvoq scripts are tracking below consensus,…
3 ‘Strong Buy’ Dividend Aristocrat Stocks on Analysts’ Watch List
Johnson & Johnson ($JNJ), Abbott Laboratories ($ABT), and AbbVie ($ABBV) are three Dividend Aristocrat stocks rated Strong Buy by the top Wall Street analysts covering each company, according to TipRa...
AbbVie price target raised to $310 from $296 at Morgan Stanley
Morgan Stanley raised the firm’s price target on AbbVie (ABBV) to $310 from $296 and keeps an Overweight rating on the shares. The firm adjusted its models for its biopharma…
AbbVie’s telisotuzumab adizutecan gets two FDA Breakthrough Therapy Designations
AbbVie (ABBV) announced that the U.S. FDA has granted two Breakthrough Therapy Designations for telisotuzumab adizutecan in colorectal cancer and non-small cell lung cancer. Temab-A has received two B...
AbbVie's Telisotuzumab Adizutecan (Temab-A) Receives Two Breakthrough Therapy Designations From the U.S. FDA for CRC and NSCLC
Temab-A is an investigational, next-generation, c-Met-directed antibody-drug conjugate (ADC) with a novel topoisomerase 1 inhibitor (Top1i) being studied in advanced solid tumors including colorectal ...
AbbVie price target raised to $320 from $280 at Scotiabank
Scotiabank analyst Louise Chen raised the firm’s price target on AbbVie (ABBV) to $320 from $280 and keeps an Outperform rating on the shares. The increased price target is driven…
AbbVie sees Q3 EPS $3.73-$3.77, consensus $3.84
The company states: “Reported GAAP earnings and adjusted non-GAAP earnings for the third quarter of 2026 are expected to include acquired IPR&D and milestones expense of $216 million on a…
AbbVie sees FY26 EPS $13.76-$13.96, consensus $14.01
16:31 EDT AbbVie (ABBV) sees FY26 EPS $13.76-$13.96, consensus $14.01
AbbVie blood cancer drug combo cuts risk of progression or death in late-stage study
Danish biotech firm Genmab and US drugmaker AbbVie said on Monday their combination treatment for patients newly diagnosed with a type of lymphoma reduced the risk of disease progression or death in...
Genmab, AbbVie report epcoritamab combination demonstrates improved PFS in study
Genmab A/S (GMAB) and AbbVie (ABBV) announced “positive” topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating fixed treatment duration epcoritamab, a T-cell engaging bispecific antibody ad...
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS)...
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
COPENHAGEN, Denmark & NORTH CHICAGO, Ill.--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) announced today positive topline results from the Phase 3 EPCORE DLBCL-2 trial evaluating ...
AbbVie joins US government pilot to test drug discount rebates
US drugmaker AbbVie said on Friday it would participate in a US government pilot program aimed at testing a new rebate system for discounted medicines.
AbbVie presents long-term RINVOQ data at EADV Congress
AbbVie (ABBV) announced late-breaking results from the ongoing Phase 3 Viti-Up-1 and Viti-Up-2 studies of RINVOQ in non-segmental vitiligo, showing continued facial and total body repigmentation throu...
AbbVie Presents Long-Term RINVOQ® (upadacitinib) Data Showing Continued Repigmentation in Non-Segmental Vitiligo
RINVOQ is the first and only systemic medication approved in the European Union to treat adult and adolescent patients with non-segmental vitiligo (NSV) who are candidates for systemic therapy Phase 3...
AbbVie to Host Third-Quarter 2026 Earnings Conference Call
NORTH CHICAGO, Ill., Oct. 1, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2026 financial results on Friday, October 30, 2026, before the market opens.
AbbVie reports Phase 1 data for ABBV-295
AbbVie (ABBV) announced that detailed results from the multiple ascending dose part of its Phase 1 study evaluating ABBV-295 will be presented in a short oral presentation at the European…
AbbVie reports ‘positive’ results from Phase 2 APEX Part B study of zumilokibart
AbbVie (ABBV) announced that the primary results from the ongoing Phase 2 APEX Part B Dose-Regimen-Finding Study, evaluating zumilokibart, in adult patients with moderate to severe atopic dermatitis w...
AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026
Detailed findings, to be presented in a short oral presentation, demonstrated an approximately 11- to 12-day half-life and dose-proportional increases in plasma exposure, supporting evaluation of ABBV...
AbbVie Highlights Positive Results from the Phase 2 APEX Part B Study of Zumilokibart in Moderate to Severe Atopic Dermatitis, as a Late Breaker at EADV 2026
Phase 2 data in adults with atopic dermatitis showed that all three zumilokibart dose regimens met the primary endpoint, with significantly greater improvements in Eczema Area and Severity Index -75 (...
AbbVie Showcases Leadership in Dermatology Research With New Clinical and Real-World Evidence Across Immune-Mediated Skin Diseases at 2026 EADV Congress
AbbVie presents 60 abstracts and presentations from a robust portfolio spanning across alopecia areata, atopic dermatitis, hidradenitis suppurativa, non-segmental vitiligo, psoriasis and psoriatic art...
AbbVie partners with Valkai to apply advanced AI across clinical development
AbbVie (ABBV) is investing in its AI infrastructure through a new partnership with Valkai, a life sciences AI platform designed to help accelerate the pace at which scientific innovation reaches…